Clinical Trial Search

Phase 3 N=103 TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF

Rheumatoid Arthritis

Primary: Percentage of Participants With Clinically Significant Improvement in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 4 — 42.0; 49.1 percentage of…

Hoffmann-La Roche Results Sep 2014 23.3% serious AE View details

Phase 3 N=341 Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan

Bacterial Meningitis

Primary: Percentage of Overall Subjects With Seroresponse, Directed Against Neisseria Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination — 83; 93; 50; 65…

Novartis Results Sep 2014 0.3% serious AE View details

Phase 3 N=545 Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD

Cervical Degenerative Disc Disease

Primary: Rate of Overall Success — 70.4; 63.2 percentage of participants — p=0.995

Medtronic Spinal and Biologics Results Sep 2014 42.4% serious AE View details

Phase 3 N=74 Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence

Smoking Cessation

Primary: Change in the Skin Conductance Level, Caused by Smoking Cues, Measured Using Script Driven Imagery — 0.107; -0.040 µS — p=0.05

Massachusetts General Hospital Results Sep 2014 1.4% serious AE View details

Phase 3 N=130 Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

Refractory Multiple Myeloma · Stage II Multiple Myeloma · Stage III Multiple Myeloma

Primary: CR and Near CR Rates — 39; 22 percentage of participants

Fred Hutchinson Cancer Center Results Sep 2014 0.0% serious AE View details

Phase 3 N=901 A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

Primary: Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16 — 41.87; 59.17; 9.04 percentage of…

Pfizer Results Sep 2014 5.8% serious AE View details

Phase 3 N=960 A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

Primary: Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16 — 46.01; 59.09; 10.88 percentage of…

Pfizer Results Sep 2014 5.1% serious AE View details

Phase 3 N=1,516 Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

Primary: Annualized Relapse Rate (ARR) at 1 Year — 0.397; 0.288; 0.256 relapses per person-years — p=0.0114

Biogen Results Sep 2014 13.5% serious AE View details

Phase 3 N=43 Genotropin Treatment In Very Young Children Born Small For Gestational Age

Infant, Small for Gestational Age

Primary: Change From Baseline in Height Standard Deviation Score (SDS) at Month 24. — 1.63; 0.43 SDS — p=<0.001

Pfizer Results Sep 2014 18.6% serious AE View details

Phase 3 N=1,010 Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic

HIV · Sexually Transmitted Diseases · HIV Infections

Primary: Number of Sexual Partners, 3 Months Post Intervention — 2.19; 2.04; 2.14; 2.13 number of partners

The Miriam Hospital Results Sep 2014 0.0% serious AE View details

Phase 3 N=1,281 Rapid HIV Testing and Counseling in Drug Abuse Treatment

Substance-Related Disorders

Primary: Self-Report Receipt of HIV Test Results — 78; 338; 347 participants — p=<0.001

University of Miami Results Sep 2014 0.5% serious AE View details

Phase 3 N=285 Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis

Primary: Number of Participants With Adverse Events — 77; 18; 92; 90 participants

Astellas Pharma Inc Results Sep 2014 23.9% serious AE View details

Phase 3 N=342 A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg

Chronic Obstructive Pulmonary Disease

Primary: Clinical Response in the Clinical Populations — 86.71; 86.26 percentage of participants

Dong Wha Pharmaceutical Co. Ltd. Results Sep 2014 0.0% serious AE View details

Phase 3 N=165 Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)

Migraine Disorders · Heart Disease · Cerebrovascular Accident

Primary: Percentage of Participants With Pain Freedom at 2 Hours Post-dose (Period 1, Migraine Attack 1) — 25.0; 18.9 Percentage of participants — p=0.329

Merck Sharp & Dohme LLC Results Sep 2014 0.5% serious AE View details

Phase 3 N=208 Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis

Primary: Number of Participants With Adverse Events — 102; 12; 41; 40 participants

Astellas Pharma Inc Results Sep 2014 36.5% serious AE View details